Treatment options for early, HR+, HER2- Breast Cancer - report from SABCS2022

from Medical Digest & Congress Report · host Medical Congress News

Professor Hope Rugo were speaker and co-author of several presentations at this years San Antonio Breast Cancer Symposium. We asked her about early stage HR+, HER2-negative breast cancer. For example, updated results of TAILORx trial on the need for adjuvant chemo and the 42 months data of the MonrachE trial. Video: https://medicaldigest.org/scientific-contents/interview:treatment-options-early-hr-her2-breast-cancer

Episode metadata supplied by the publisher feed · Published Jan 10, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Treatment options for early, HR+, HER2- Breast Cancer - report from SABCS2022

0:00 13:11

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 13 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on January 10, 2023.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!